Sinopharm Holdings (01099.HK): Main business maintains growth trend, transformation and innovation continue to advance
Damo: Target price for Sinopharm Holdings (01099) “increase in holdings” rating reduced to HK$28
Sinopharm Holdings (1099.HK): Shareholders' equity increased 6.2% year-on-year in '23, gross margin is still declining
Sinopharm Holdings (1099.HK): 2023 results slightly lower than expected; high dividend rate expected to continue
Sinopharm Holdings (1099.HK): Expense Control Continues to Deepen and Expect Steady Growth in Performance
Sinopharm Holdings (01099.HK): Performance is in line with expectations, and the cost rate is further optimized
Daehan Rating | Daiwa: First Sinopharm Holdings “Buy” Rating and Target Price HK$25
Nomura Adjusts Sinopharm Group's Price Target to HK$32.39 Form HK$33.31, Keeps at Buy
Daimo: Yosinopharm Holdings (01099) “increase in holdings” rating, target price lowered to HK$29
Research Report Nuggets | CICC: Lowering the target price of Sinopharm Holdings to HK$26 due to a decline in the average valuation of the industry
Sinopharm Holdings (1099.HK): Short-term performance under pressure, optimistic about Q4 month-on-month improvement
Sinopharm Holdings (01099.HK): Performance was in line with expectations, sales and financial expenses declined slightly in the 1st to 3rd quarter
Bank Ratings|Dahua Jixian: Maintaining Sinopharm Holdings' “Buy” Rating, Target Price Lowered to HK$25
Nomura: Maintaining the “buy” rating of Sinopharm Holdings (01099), the target price dropped to HK$33.31
Research Report Nuggets | Huatai Securities: Maintaining Sinopharm Holdings's “buy” rating target price of HK$32.36
Sinopharm Holdings (1099.HK): H1's performance is growing steadily, and the advantages of integrated transformation are obvious
Citigroup: Maintains the “buy” rating of Sinopharm Holdings (01099) and lowers the target price to HK$26
Sinopharm Holdings (01099.HK): Performance is in line with expectations, retail operating profit margin increases
Sinopharm Holdings (1099.HK): Three major businesses are strong, and market share continues to be consolidated
Nomura: Maintaining Sinopharm Holdings' (01099) “Buy” Rating Target Price Reduced to HK$36.28
No Data